Dr. Lal Pathlabs News and Updates

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Dr. Lal Pathlabs from all sources in a single place.

Dr. Lal Pathlabs Ltd.

06 Jan 2026

1381.00

-2.62%

Dr Lal PathLabs Bets On Preventive Healthcare, Launches Premium Wellness Brand Sovaaka

NDTV Profit

The launch comes at a time when Dr Lal PathLabs continues to rely on volume-led growth, having not taken a price hike in the last three years despite inflationary pressures.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

31 Dec 2025

1381.00

-2.62%

HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target

Business Standard

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Dr. Lal Pathlabs Ltd.

30 Dec 2025

1381.00

-2.62%

Dr. Lal Pathlabs Shares Upgraded By HDFC Securities Check Target Price, Potential Upside And More

NDTV Profit

Dr. Lal's strong execution in core markets, expansion into new geographies, and innovation-led portfolio enhancement underpin brokerage's positive stance.

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Dr. Lal Pathlabs Ltd.

18 Dec 2025

1381.00

-2.62%

Dr. Lal PathLabs shares turn ex-bonus tomorrow for 1:1 issue, last day to buy for eligibility

Economic Times

As per the corporate filings, the company will issue one fully paid-up bonus equity share of face value Rs 10 for every one existing fully paid-up equity share of Rs 10 held by shareholders as on the record date.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

14 Dec 2025

1381.00

-2.62%

Corporate Actions This Week: Dr Lal PathLabs Bonus Issue; Can Fin Homes To Trade Ex-Dividend Full List

NDTV Profit

eClerx Services will trade ex-date for their Buy Back of Shares on Dec. 17, 2025.

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Dr. Lal Pathlabs Ltd.

31 Oct 2025

1381.00

-2.62%

Dr Lal PathLabs Q2 results: PAT up 16.4% at 152 crore, revenue rises 11%

Business Standard

Diagnostics chain declares 7 per share interim dividend, 1:1 bonus issue

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

31 Oct 2025

1381.00

-2.62%

to see Rapid results content

Dr. Lal Pathlabs Ltd.

14 Sep 2025

1381.00

-2.62%

Eye helpline launched to connect patients nationwide with Delhi doctors

Business Standard

Making eye care accessible to citizens, a team of leading ophthalmologists in Delhi have launched a national eye helpline number to connect doctors with patients from all over the country. The initiative, spearheaded under the banner of Sight Sarthi India Foundation, a not-for-profit organisation, promises free telephonic and video consultations for anyone across the country struggling with eye problems. Headed by Dr Ikeda Lal, cornea, cataract and refractive surgeon and medical director at Delhi Eye Centre, the helpline is set to become a lifeline for millions - especially those in remote towns and villages who often struggle to access quality ophthalmic care. With a dedicated team of leading ophthalmologists from Delhi, the project is designed to break barriers of geography, cost, and access. From cataract and refractive errors to preventable blindness, millions either delay or avoid treatment due to lack of access or high cost of travel, Dr Lal said. "The newly launched helplin

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

02 Sep 2025

1381.00

-2.62%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab...

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Dr. Lal Pathlabs Ltd.

20 Aug 2025

1381.00

-2.62%

Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool

Business Standard

Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Is Dr. Lal Pathlabs Ltd. worth buying?

231 Votes:

Buy 76.19%

Sell 14.72%

Hold 9.09%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf